# Reducing Adeno-Viral Patient Infected Days:  Secondary Analyses

> **NIH NIH R21** · WASHINGTON UNIVERSITY · 2020 · $196,875

## Abstract

Project Summary
In the 21st century, adenoviral conjunctivitis (Ad-Cs) continues to be an eye infection of epidemic
potential that can cause marked symptomatology, work-flow stoppages and significant
economic losses. There is no FDA approved treatment for adenoviral conjunctivitis. A treatment
that reduces the 5-12 day period of transmission and/or infection even by a few days would
have significant public health and economic impact.
“Reducing Adenoviral Patient-Infected Days” (RAPID), is a double-masked, randomized
planning study of the efficacy of an in-office administration of 5% povidone iodine (PVP-I)
compared to artificial tears to reduce duration and severity of Ad-Cs. Data collected at each
visit include patient self-reported symptoms, clinical signs and conjunctival swab taken for
adenoviral qPCR, IL-8, 16S amplicon sequencing. Of the 212 participants who were
successfully screened, 56 tested positive for adenovirus by immunoassay and were randomized
to receive either 5% PVP-I or artificial tears. Post-randomization visit completion rates at 1-2
days, 4, 7, 14 and 21 days were 88%, 75%, 79%, 63% and 68% respectively.
The Data and Safety Monitoring Committee reviewed final results September 18, 2019 and
recommended analysis/publication of several secondary analyses. Cross-sectional data for
participants presenting with “pink eye” and longitudinal data for randomized participants provide
an unprecedented opportunity to examine relationships between phenotypic data, 16S amplicon
sequencing, qPCR and IL-8 (Aim A). Screening data from patient self-report and clinical signs
provide strong evidence that a multivariate clinical prediction model could be developed to
improve diagnostic accuracy of Ad-Cs in primary care practices where most patients with “pink
eye” seek treatment (Aim B). All data reside in secure, de-identified datasets at the Washington
University in St. Louis Coordinating Center ready for secondary analyses. This R-21 Secondary
Analysis grant will support analysis, submission and publication of manuscripts from these 2
broad Aims within the 24 month funding period.

## Key facts

- **NIH application ID:** 9999598
- **Project number:** 5R21EY030524-02
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** MAE O GORDON
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $196,875
- **Award type:** 5
- **Project period:** 2019-09-01 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9999598

## Citation

> US National Institutes of Health, RePORTER application 9999598, Reducing Adeno-Viral Patient Infected Days:  Secondary Analyses (5R21EY030524-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9999598. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*